Navigation Links
New culprit discovered in T-cell acute lymphoblastic leukemia
Date:1/12/2012

A new study published in the journal Nature Medicine by NYU Cancer Institute researchers, shows how the cancer causing gene Notch, in combination with a mutated Polycomb Repressive Complex 2 (PRC2) protein complex, work together to cause T- cell acute lymphoblastic leukemia (T-ALL).

T-ALL is an aggressive blood cancer, predominately diagnosed in children. It occurs when one lymphoblast, an immature white blood cell, turns malignant, multiplying uncontrollably and spreading rapidly throughout the body. If left untreated, the disease can be fatal in a few weeks. Cancer-causing Notch mutations in T-ALL are well established, yet the detailed molecular mechanism mediating this Notch-induced cancer cell transformation was unknown until now.

"Our study presents new insight into how Notch acts in an antagonistic mode with PRC2 to promote T-ALL," said senior author, Iannis Aifantis, PhD, associate professor in the Department of Pathology and a member of the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center. "Moreover, our study shows frequent genetic inactivation on the genetic loci encoding for PRC2 components, inhibits its normal role as a gene expression regulator and further proves the tumor suppressor role of the complex in this disease."

The study shows a new dynamic interplay between Notch and PRC2 function. In the study, researchers analyzed Notch-driven epigenetic gene expression regulation changes in T-ALL. Findings show a clear loss of PRC2 function from the sites of Notch1 binding. In addition, researchers found recurrent gene mutations and deletions of the components of PRC2 in T-ALL patient samples. In the study, loss of PRC2 function fueled the Notch mutation. This provides evidence for a central role of deregulation of PRC2 in Notch-induced T-ALL.

"The inactivation of PRC2 complex due to Notch in T-ALL constitutes an important pathogenetic event in the formation of this potentially deadly disease," said lead author of the study Panagiotis Ntziachristos, PhD, of the Department of Pathology at NYU Langone. "The PRC2 genetic alteration amplifies the Notch oncogene's communication signals leading to T-ALL. Our study experiments uncover a specific epigenetic switch during the progression of the disease that can be further exploited for the development of targeted epigenetic therapies."

The study shows T-ALL as an epigenetic disease, regulated by a subtle equilibrium between oncogenes and tumor suppressors. Oncogenes like Notch can infiltrate the normal function of PRC2 in specific gene loci leading to cancerous cell transformation. Mutations in PRC2 assist oncogenes like Notch by altering their DNA gene expression.

"Our studies offer new therapy avenues for the treatment of T-ALL," said Dr. Aifantis. "The detection of new genetic alterations in T-ALL provides a new platform for selecting potential treatment strategies for the disease. Drugs that can target histone demethylases, enzymes that catalyze the H3K27me3 modification, could be used alone or in combination with Notch1 inhibitors for the treatment of the disease."


'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers discover new culprit in atherosclerosis
2. Extra Calories, Low Protein Are Culprits in Weight Gain
3. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
4. New culprit found in Lou Gehrigs disease
5. Researchers search for culprit behind dry eyes, mouths and more
6. Key culprit identified in breast cancer metastasis
7. Lung cancer culprit could offer target for therapy, UT Southwestern researchers report
8. Researchers identify breast cancer culprits
9. Gene discovered for Weaver syndrome
10. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
11. A better way to count molecules discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover ... he was inspired to practice medicine at an early age by his father, who ... making diagnoses and prescribing medicine,” he states. “It is about building relationships with people; ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Health" in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized ... fulfilling lives. “We are prolonging life 6 years in the last 3 decades,” ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... ... and pharmaceutical organizations to build intelligent, connected applications, was named the best Sales ... , The winner announcement was made today by the Software & Information ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the ... while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that there ... this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... In the first ever attempt to include ... from C. sativa, the Hebrew University in Jerusalem, the ... II , the Universita` del Piemonte Orientale and Phytoplant ... and unified inventory of phytocannabinoids of different botanical origin. ... remarkable chemical and structural diversity of phytocannabinoids. As a ...
(Date:12/2/2016)... -- Maxor National Pharmacy Services, LLC ("Maxor"), today announced that it ... combination of Texas -based Maxor Specialty / ... together both company,s clinical expertise and high-touch patient service models ... pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... December 2, 2016 Orthopedic Implants (Including ... is Expected to Gain a Significant Market Share Owing to ... ... According to a new report ... Implants Sterile Packaging: Clamshell Product Type Segment Projected to Witness ...
Breaking Medicine Technology: